good morning america semaglutide New study shows Ozempic lowers kidney disease Woman shares journey of weight

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist is its safety profile acceptable

Harris, S., Liu, Y., & Nguyen, P

SGLT2 inhibitors in Heart failure: targeted metabolomics and energetic metabolism

What the evidence does not show: No randomized trial has demonstrated meaningful weight loss, cardiovascular benefit, or metabolic benefit from weekly semaglutide doses below 0.25 mg

It may be reasonable if you have an amount of weight to lose can access a legitimate source can sustain the cost indefinitely as supply tightens and prices likely rise and do not qualify for or do not want surgery